MedTrace Logo

A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04462185 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-05-24

No results posted yet for this study

Summary

The broad goals of this study is to identify changes in genomic landscape during transition from stage 0 to stage 1 lung cancer.

This study intends to determine whether diagnostic biomarkers measured in minimally invasive biospecimens are able to correlate molecular, clinical and imaging features to distinguish malignant from benign pulmonary nodules. The diagnostic markers once validated can be used as broad screening tools for lung cancer.

Conditions

  • Pulmonary Nodules

Interventions

DIAGNOSTIC_TEST

A genomic and transcriptomic landscape analysis

A genomic and transcriptomic landscape analysis will be developed to identify and characterize the transcriptome of benign versus malignant by using RNA sequencing, and to profile cfDNA in blood samples collected from patients with pulmonary nodules.

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Beijing Chao Yang Hospital

    collaborator OTHER

  • Johnson & Johnson (China) Investment Ltd.

    collaborator INDUSTRY

  • AnchorDx Medical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Nanshan ZHONG, MD · The First Affiliated Hospital of Guangzhou Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462185 on ClinicalTrials.gov